Compass Therapeutics Inc. stocks have been trading down by -7.88 percent after sentiment turned negative on its latest clinical trial news.
Click Here for a Millionaire's POV on Trading CMPX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Shares collapsed roughly 24% after the COMPANION-002 Phase 3 trial showed lead drug tovecimig failed the overall survival secondary endpoint in biliary tract cancer.
- Median overall survival for tovecimig came in slightly worse than control, and a complex RPSFT statistical adjustment for crossover was deemed largely uninterpretable.
- Raymond James cut CMPX from Outperform to Market Perform, calling the survival readout a “true bear” scenario and slashing expectations for approval and commercialization.
- Law firm Johnson Fistel opened an investigation into potential securities law violations and shareholder losses tied to CMPX’s handling of COMPANION-002 results.
Live Update At 12:32:17 EDT: On Wednesday, April 29, 2026 Compass Therapeutics Inc. stock [NASDAQ: CMPX] is trending down by -7.88%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
CMPX has gone from a smooth uptrend to a full-on collapse in less than a week. On 2026/04/24, Compass Therapeutics closed near $5.03. By 2026/04/29, after the COMPANION-002 failure hit the tape, CMPX finished around $1.70. That’s a drawdown of roughly two-thirds of its value, the kind of move traders usually only see when a biotech thesis breaks.
Intraday trading on the latest session shows CMPX cycling between about $1.64 and $1.91, with tight five‑minute candles and no real trend. That tells traders the initial panic flush may be done, but confidence is still fragile and day traders are now dominating the tape.
More Breaking News
- SNPS Extends TSMC, Atomera Alliances As Legal Risks Surface
- SES AI Stock Slides As Legal Probes Mount And $300M Shelf Filed
- ONDS Stock Builds Defense Backlog As Analysts Turn Bullish
- RIOT Stock Tests Support As Volatility Grips Crypto Miners
On the fundamentals, Compass Therapeutics is classic clinical‑stage biotech: revenue-light, loss-heavy, but cash-rich. CMPX posted a quarterly net loss of about $15.7M and negative operating cash flow of roughly $13.3M. Yet the balance sheet shows around $31.2M in cash and over $208.9M in cash and short-term investments, backed by a strong current ratio near 15 and very low debt. For traders, that means CMPX is not a near-term bankruptcy story; the real risk is pipeline value, not balance sheet survival.
Why Traders Are Watching CMPX After The “True Bear” Data
CMPX is now the textbook example of why biotech trading is unforgiving when late-stage data disappoints. Compass Therapeutics had pinned a lot of its story on tovecimig (CTX‑009) in second‑line biliary tract cancer. The Phase 3 COMPANION‑002 trial was supposed to be a major value driver. Instead, the company reported that tovecimig failed to meet the overall survival secondary endpoint, and median survival actually came in slightly worse than the control arm.
The company also leaned on a rank‑preserving structural failure time (RPSFT) adjustment to account for heavy crossover from the control arm. That kind of adjustment can sometimes rescue a damaged survival signal. Here, it did not. Compass Therapeutics said the RPSFT analysis was largely uninterpretable. For CMPX traders, that removed a key “maybe the stats save us” bull hope.
The tape reacted brutally. CMPX dropped roughly 24% on the news, and the multiday chart shows a straight line down from the $5s into the $1s. That’s more than just weak hands bailing; it’s institutions re‑rating the entire business. Raymond James followed by downgrading CMPX from Outperform to Market Perform, calling the Phase 3 survival data a “true bear” scenario and slashing confidence in both regulatory approval and commercialization.
On top of that, law firm Johnson Fistel announced an investigation into possible securities law violations and shareholder losses around Compass Therapeutics and COMPANION‑002. Even if nothing comes of it, legal headlines add another overhang. For active traders, this triple hit — trial failure, downgrade, and legal probe — sets CMPX up as a volatile battleground where sentiment, not fundamentals, is running the show for now.
Conclusion
CMPX now sits in a very different place on traders’ watchlists than it did just days ago. Before the COMPANION‑002 readout, Compass Therapeutics was a clinical‑stage name with a clean balance sheet and a promising late‑stage asset. After tovecimig’s survival miss, the CMPX story is about damage control, pipeline reassessment, and whether any bounce is real or just a dead‑cat move.
The fundamentals still matter. CMPX has over $200M in cash and investments and minimal leverage, giving Compass Therapeutics time to regroup and focus on other programs. But the market won’t pay up for cash alone. It wants a credible path to future drugs and, after this Phase 3 failure, traders will demand clearer data and more conservative expectations on every update. In this kind of name, pattern recognition is everything for active market participants. As Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.” For CMPX, that means studying how the stock behaves around headlines, key levels, and liquidity shifts rather than blindly chasing every spike.
For short‑term traders, CMPX is now a pure volatility vehicle. The 24% crash, tight intraday ranges, and heavy news flow create the kind of environment momentum players love — and blow up in, if they get stubborn. Risk management has to come first. As Tim Sykes always reminds traders, “Cut losses quickly, because holding and hoping is how small mistakes turn into blown-up accounts.” CMPX is a live example of why that rule exists. This analysis is for educational and research purposes only, but the lesson from Compass Therapeutics is clear: respect the data, respect the chart, and always have an exit plan.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.